CDC's 2019 AR Investment Map
Click left or right to see more factsheets.
Local health department that received additional funding.
Location of one of seven AR Laboratory Network regional labs.
Location of the National Tuberculosis Molecular Surveillance Center.
This map represents CDC’s largest funding categories for antibiotic resistance. It shows extramural funding that supports AR activities from multiple funding lines.
Antibiotic resistance (AR), when germs do not respond to the drugs designed to kill them, threatens to return us to the time when simple infections were often fatal. CDC is committed to protecting people and the future of the healthcare, veterinary, and agriculture industries from the threat of antibiotic resistance.
The AR Investment Map showcases CDC’s critical activities in the United States and abroad to combat antibiotic resistance with investments in laboratory and epidemiological expertise and public health innovation.
CDC supports most of these activities through its AR Solutions Initiative, while also leveraging investments from successful programs across the agency for maximum efficiency.
Since 2016
to
local AR experts
AR Lab Network detects a resistant germ that requires investigation every
Whole genome sequencing on
Laboratory & Diagnostics: Gold-standard lab capacity offered to all U.S. state and regional labs through CDC’s AR Laboratory Network, and on-the-ground lab expertise and assistance in some countries abroad
Epidemiology Capacity for Response: Increased capacity in state and local health departments and some countries for rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread
Surveillance & Science: More effective tracking and prevention of healthcare-associated infections, foodborne illness, and gonorrhea
Improved Antibiotic Use: Improving antibiotic use to ensure antibiotics are available and work to protect people from life-threatening infections or sepsis
Insights for Practice: Innovations and collaborations with academic and healthcare partners to identify and implement new ways to prevent antibiotic-resistant infections and their spread in the U.S. and abroad
Research and Development: Sharing isolates that inform development of new drugs and diagnostics, and making public CDC’s sequencing data from AR pathogens to spur innovation in industry
See Investments by Location
- About CDC's Work to Combat AR
- Global Summary
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
- Guam
- Puerto Rico
- Virgin Islands, U.S.
- Chicago, IL
- Houston, TX
- Los Angeles County, CA
- New York City, NY
- Philadelphia, PA
Antibiotic Resistance Investments - Version 1.13.01.01